The strongest evidence is for PDCD1, which meets all five criteria: nearby GWAS hit, protein association, Mendelian randomization support, validation from perturbation in an experimental model, and effects of a targeted agonist against rheumatoid arthritis in a phase 2 trial. This evidence concerns the gene PDCD1 and rheumatoid arthritis.